Nasal Human Abuse Potential of PTI-821

A Randomized, Double-Blind, Placebo-Controlled, Double-Dummy, Single-Dose,4-Way Crossover Study With Exploratory Fifth Treatment to Determine the Relative Nasal Abuse Potential of PTI-821 (Oxycodone Extended-Release Capsules)

The study will evaluate the human abuse liability of PTI-821 (oxycodone extended-release capsules) when administered nasally compared to crushed oxycodone IR tablets and crushed OxyContin tablets, also administered nasally.

Study Overview

• Status: Completed
• Conditions: Opioid Abuse Nondependent
• Intervention / Treatment: Drug: PTI-821 capsule Manipulated; Drug: Oxycodone; Drug: OxyContin; Other: Placebo; Drug: PTI-821 Non-manipulated

Detailed Description

The nasal human abuse liability of PTI-821 will be compared to oxycodone IR using pharmacokinetic and pharmacodynamic assessments. A comparison to OxyContin will be dose using pharmacokinetic assessments.

• Study Type: Interventional
• Enrollment (Actual): 38
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • Utah
    • Salt Lake City, Utah, United States, 84106
      • PRA-EDS

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 14 years to 51 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria::

• Healthy male and/or female subjects between the ages of 18 and 55 years,
• Subject is a recreational opioid user who is NOT dependent on opioids
• Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and body weight > 50 kg (110lbs).
• Evidence of a personally signed and dated informed consent document
• Subjects must be willing and able to comply with study procedures.
• Females who are physically incapable of childbearing, or practicing an acceptable method of birth control. Acceptable methods of birth control include surgical sterilization, hormonal contraceptives, or double-barrier methods (condom or diaphragm with a spermicidal agent or intrauterine device).

Exclusion Criteria:

• Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
• Diagnosis of substance and/or alcohol dependence (excluding caffeine and nicotine).
• Has participated in, is currently participating in, or is seeking treatment for substance- and/or alcohol-related disorders (excluding nicotine and caffeine).
• Has a positive urine drug screen (UDS) excluding tetrahydrocannabinol (THC) at Screening and the admission for Qualification Phase.
• Has a positive alcohol breath test at Screening or upon admission to the study center for the Qualification Phase.
• Has any history of a condition in which an opioid is contraindicated
• History of sleep apnea in the past 5 years that has not been resolved.
• Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject unsuitable for entry into this study.
• Positive test for Hepatitis B, Hepatitis C, or HIV at Screening.
• Allergy or history of hypersensitivity to naloxone hydrochloride (HCl), oxycodone HCl, other opioids, and/or lactose.
• Any condition possibly affecting drug absorption.
• Physical (eg, constricted or collapsed veins) or mental obstruction (ie, phobia) that would prevent serial blood sample collection.
• Clinically significant illness in the judgment of the investigator within 30 days before Screening.
• Treatment with an investigational drug within 30 days (or as determined by the local requirement, whichever is longer) or 5 half-lives preceding the first treatment during the Qualification Period (Visit 2), if longer than 30 days.
• Screening BP > 140 mm Hg (systolic) or > 90 mm Hg (diastolic) following at least 5 minutes of rest. If BP is > 140 mm Hg (systolic) or > 90 mm Hg (diastolic), the BP should be repeated two more times and the average of the three BP values should be used to determine the subject's eligibility.
• Pregnant females; breastfeeding females; males and females of childbearing potential who are unwilling or unable to use a highly effective method of contraception as outlined in this protocol for the duration of the study and for 28 days after the last dose of study medication. Urine pregnancy tests must be collected and confirmed negative prior to dosing upon admission.
• Is currently taking a drug for a medical condition or a nutraceutical that poses a safety risk when administered with an opioid, cannot be safely withdrawn at Screening for the duration of the study, and/or will adversely affect the PD and safety assessments required by the study. Examples include antihypertensive agents, drugs for seizures, and diabetes medications. Hormonal contraceptives (oral, injected, intrauterine, transdermal or implanted) are allowed in this study provided the subject remains on the same treatment throughout the entire study and has been using that hormonal contraceptive for an adequate period of time to ensure effectiveness. Limited use of non-prescription medications that are not believed to affect subject safety or the overall results of the study may be permitted on a case-by-case basis following approval by the investigator. As an exception, acetaminophen may be used at doses of 1 g/day.
• Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 30 days prior to dosing.
• Unwilling or unable to comply with the procedures described in this protocol.
• Unwilling to be searched (including personal effects) for illicit substances before admission to the study center.
• Subject is a heavy smoker (> 20 cigarettes per day on average in the past 30 days prior to Screening), chews tobacco, uses nicotine-containing products (including nicotine transdermal patches), and/or is unable to abstain from smoking for at least 10 hours during any day.
• Current pending legal charges or currently on probation.
• Subjects who are investigational site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or subjects who are PTI employees directly involved in the conduct of the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: Quadruple

Number of Arms

5

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: PTI-821 Manipulated; oxycodone 40 mg capsule	Drug: PTI-821 capsule Manipulated; PTI-821 (oxycodone) 40 mg extended release capsule
Active Comparator: Oxycodone; Oxycodone 40 mg IR tablet crushed	Drug: Oxycodone; Crushed oxycodone 40 mg immediate release tablet
Active Comparator: OxyContin; Oxycodone ER 40 mg tablet crushed	Drug: OxyContin; Crushed OxyContin (oxycodone) extended-release 40 mg tablet
Placebo Comparator: Placebo; Matching placebos for experimental and active comparator arms	Other: Placebo; Matching placebos for PTI-821 and oxycodone IR
Experimental: PTI-821 Non-manipulated; Oxycodone 40 mg non-manipulated	Drug: PTI-821 Non-manipulated; PTI-821 (oxycodone) 40 mg capsule extended release capsule

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Drug Liking Emax	Peak effect for drug liking based on bipolar visual analog scale from 0-100 where 0 is most negative response, 50 is neutral, and 100 is most positive response.	Intervals from 0.5 hours to 12 hours post dose

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Take Drug Again	Desire to take drug again if offered based on bipolar visual analog scale from 0-100 where o is most negative response, 50 is neutral, and 100 is the most positive response.	12 and 25 hours
Drug effects questionnaire	Assesses various drug effects such as good drug effects, bad drug effects, high and nausea/dizziness	Intervals from 0.5 hours to 12 hours post dose
Peak Plasma Concentration (Cmax)	Maximum plasma concentration	Intervals from 15 minutes to 24 hours post-dose
Area under the plasma concentration versus time curve	Amount of drug absorbed at various timepoints	Intervals from 15 minutes to 24 hours post-dose
Time to maximum plasma concentration (Tmax)	The time intervals from the first dose to the peak plasma concentration	Intervals from 15 minutes to 24 hours post-dose

Collaborators and Investigators

• Sponsor: Pain Therapeutics
• Collaborators: PRA Health Sciences
• Investigators: Principal Investigator: Lynn Webster, MD, PRA Health Sciences

Study record dates

Study Major Dates

• Study Start (Actual): May 15, 2017
• Primary Completion (Actual): July 31, 2017
• Study Completion (Actual): December 15, 2017

Study Registration Dates

• First Submitted: March 7, 2018
• First Submitted That Met QC Criteria: March 22, 2018
• First Posted (Actual): March 23, 2018

Study Record Updates

• Last Update Posted (Actual): March 23, 2018
• Last Update Submitted That Met QC Criteria: March 22, 2018
• Last Verified: March 1, 2018

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Mental Disorders; Chemically-Induced Disorders; Substance-Related Disorders; Narcotic-Related Disorders; Opioid-Related Disorders; Physiological Effects of Drugs; Central Nervous System Depressants; Peripheral Nervous System Agents; Analgesics; Sensory System Agents; Analgesics, Opioid; Narcotics; Oxycodone
• Other Study ID Numbers: PTI-821-C08

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No